Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer

Authors: Patricia Piña-Sánchez, Dulce María Hernández-Hernández, Lucia Taja-Chayeb, Ricardo M. Cerda-Flores, Ana Lilia González-Herrera, Carlos Rodea-Avila, Teresa Apresa-García, Patricia Ostrosky-Wegman, Guelaguetza Vázquez-Ortíz, Patricia Mendoza-Lorenzo, Alfonso Dueñas-González, Mauricio Salcedo

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

Cervical cancer (CC) is the second most common cancer in Mexican women. Human papillomavirus (HPV) infection is necessary but not sufficient for CC development. Furthermore, genetic factors as polymorphisms could be important susceptibility factors. Controversial results regarding TP53 polymorphisms specifically in codon 72 of CC have been reported. In the present work, the exon 4 sequence of TP53 gene in CC and healthy Mexican-mestizo women were analyzed. A group of 111 women with CC and 126 healthy women (control) were included. Peripheral blood cells for polymorphism analysis and cervical scrape for HPV detection were used. PCR of exon 4 of TP53 were subjected to denaturing high-performance liquid chromatography (DHPLC) analysis and sequencing. HPV detection was subjected to PCR and sequencing. The statistical analysis was carried out using the Arlequin software. Codon 72 Arg/Arg was the most common SNP detected, and Hardy–Weinberg analysis showed equilibrium in control and CC samples (P > 0.05). Wild type sequence of TP53 exon 4 was detected in 66 and 57% in control and CC samples, respectively. For codon 72 Arg/Arg, differences between control and CC women were found (P = 0.043). An association between HPV 16/18 infection and 72 Arg/Arg in woman with CC was found (P = 0.026). Haplotype GC (codon 36 and 72) was statistically significantly associated with CC (P = 0.011). HPV 16 was the most common viral type. Codon 72 Arg/Arg is the most common polymorphism in the Mexican population and could be associated to HPV 16 and/or HPV 18 infection in CC.
Literature
2.
go back to reference Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef
3.
go back to reference Castellsague X, Bosch FX, Muñoz N. Environmental co-factors in HPV carcinogenesis. Virus Res. 2002;89:191.PubMedCrossRef Castellsague X, Bosch FX, Muñoz N. Environmental co-factors in HPV carcinogenesis. Virus Res. 2002;89:191.PubMedCrossRef
4.
go back to reference Kirk B, Feinsod M, Favis R, Kliman RM, Barany F. Single nucleotide polymorphism seeking long term association with complex disease. Nucleic Acids Res. 2002;30:3295–311.PubMedCrossRef Kirk B, Feinsod M, Favis R, Kliman RM, Barany F. Single nucleotide polymorphism seeking long term association with complex disease. Nucleic Acids Res. 2002;30:3295–311.PubMedCrossRef
5.
go back to reference Storey A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–34.PubMedCrossRef Storey A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–34.PubMedCrossRef
6.
go back to reference Thomas M, et al. Two Polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cel Biol. 1999;19:1092–100. Thomas M, et al. Two Polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cel Biol. 1999;19:1092–100.
7.
go back to reference Jee SH, et al. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet. 2004;85:301–8.PubMedCrossRef Jee SH, et al. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet. 2004;85:301–8.PubMedCrossRef
8.
go back to reference Makni H, et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer. 2000;87:528–33.PubMedCrossRef Makni H, et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer. 2000;87:528–33.PubMedCrossRef
9.
go back to reference Cohen V, et al. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer. 2006;107:2858–65.PubMedCrossRef Cohen V, et al. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer. 2006;107:2858–65.PubMedCrossRef
10.
go back to reference Gross E, Kiechle M, Arnold N. Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem Biophys Methods. 2001;47:73–81.PubMedCrossRef Gross E, Kiechle M, Arnold N. Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem Biophys Methods. 2001;47:73–81.PubMedCrossRef
11.
go back to reference Terris MK, Peehl DM. Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology. 1997;50:150–6.PubMedCrossRef Terris MK, Peehl DM. Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology. 1997;50:150–6.PubMedCrossRef
12.
go back to reference Manos M. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. In: Forth M, Greaves M, et al., editors. Cancer Cell 7º molecular diagnostics of human cancer. New York: Cold Spring Harbor Laboratory; 1988. p. 209–14. Manos M. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. In: Forth M, Greaves M, et al., editors. Cancer Cell 7º molecular diagnostics of human cancer. New York: Cold Spring Harbor Laboratory; 1988. p. 209–14.
13.
go back to reference Sousa H, Santos AM, Pinto D, Medeiros R. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med. 2007;20:731–41.PubMed Sousa H, Santos AM, Pinto D, Medeiros R. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med. 2007;20:731–41.PubMed
14.
go back to reference Koushik A, Platt RW. Franco EL: p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev. 2004;13:11–22.PubMedCrossRef Koushik A, Platt RW. Franco EL: p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev. 2004;13:11–22.PubMedCrossRef
15.
go back to reference Klug SJ, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10:772–84.PubMedCrossRef Klug SJ, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10:772–84.PubMedCrossRef
16.
go back to reference Zheng XZ, et al. Ethnicity determines association of p53Arg72Pro alleles with cervical cancer in China. Eur J Cancer Prev. 2008;17:460–6.PubMedCrossRef Zheng XZ, et al. Ethnicity determines association of p53Arg72Pro alleles with cervical cancer in China. Eur J Cancer Prev. 2008;17:460–6.PubMedCrossRef
17.
go back to reference Suarez-Rincon AE, Moran-Moguel MC, Montoya-Fuentes H, Gallegos MP, Sánchez-Corona JL. Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico. Ginecol Obstet Mex. 2002;70:344–8.PubMed Suarez-Rincon AE, Moran-Moguel MC, Montoya-Fuentes H, Gallegos MP, Sánchez-Corona JL. Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico. Ginecol Obstet Mex. 2002;70:344–8.PubMed
18.
go back to reference Min-Min H, Ming-Rong X, Ze-yi C, Kai-xuan Y, Zhi-lin S. Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions. Int J Gynecol Cancer. 2006;16:2004–8.PubMedCrossRef Min-Min H, Ming-Rong X, Ze-yi C, Kai-xuan Y, Zhi-lin S. Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions. Int J Gynecol Cancer. 2006;16:2004–8.PubMedCrossRef
19.
go back to reference Saranath D, et al. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol. 2002;86:157–62.PubMedCrossRef Saranath D, et al. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol. 2002;86:157–62.PubMedCrossRef
20.
go back to reference Brenna SM, et al. Prognostic value of P53 codon 72 polymorphism in invasive cervical cancer in Brazil. Gynecol Oncol. 2004;93(2):374–8.PubMedCrossRef Brenna SM, et al. Prognostic value of P53 codon 72 polymorphism in invasive cervical cancer in Brazil. Gynecol Oncol. 2004;93(2):374–8.PubMedCrossRef
21.
go back to reference Schwartz SM, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol. 2001;19:1906–15.PubMed Schwartz SM, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol. 2001;19:1906–15.PubMed
22.
go back to reference Huang LW, Chao SL, Hwang JL. Human papillomavirus-31-related types predict better survival in cervical carcinoma. Cancer. 2004;100:327–34.PubMedCrossRef Huang LW, Chao SL, Hwang JL. Human papillomavirus-31-related types predict better survival in cervical carcinoma. Cancer. 2004;100:327–34.PubMedCrossRef
23.
go back to reference Shah W, et al. The prevalence of human papillomavirus type 58 in Chinese patients with cervical carcinoma and its influence on survival. Clin Oncol (R Coll Radiol). 2009;21:768–74.CrossRef Shah W, et al. The prevalence of human papillomavirus type 58 in Chinese patients with cervical carcinoma and its influence on survival. Clin Oncol (R Coll Radiol). 2009;21:768–74.CrossRef
24.
go back to reference Hiller T, Poppelreuther S, Stubenrauch F, Iftner T. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev. 2006;15:1262–7.PubMedCrossRef Hiller T, Poppelreuther S, Stubenrauch F, Iftner T. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev. 2006;15:1262–7.PubMedCrossRef
25.
go back to reference van Duin M, et al. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol. 2000;81:317–25.PubMed van Duin M, et al. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol. 2000;81:317–25.PubMed
26.
go back to reference Bergamaschi D, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3:387–402.PubMedCrossRef Bergamaschi D, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3:387–402.PubMedCrossRef
27.
go back to reference Bojesen SE, Nordestgaard BG. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle. 2008;7:158–63.PubMedCrossRef Bojesen SE, Nordestgaard BG. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle. 2008;7:158–63.PubMedCrossRef
28.
go back to reference Koivusalo R, Hietanen S. The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status. Cancer Biol Ther. 2004;3:1177–83.PubMedCrossRef Koivusalo R, Hietanen S. The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status. Cancer Biol Ther. 2004;3:1177–83.PubMedCrossRef
29.
go back to reference Varley JM, et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene. 2001;20:2647–54.PubMedCrossRef Varley JM, et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene. 2001;20:2647–54.PubMedCrossRef
30.
go back to reference Tenti P, et al. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev. 2000;9:435–8.PubMed Tenti P, et al. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev. 2000;9:435–8.PubMed
31.
go back to reference Rosenthal AN, et al. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet. 1998;352:871–2.PubMedCrossRef Rosenthal AN, et al. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet. 1998;352:871–2.PubMedCrossRef
32.
go back to reference Tong D, et al. Detection of p53 polymorphism at codon 72 by PCR and allele-specific oligonucleotide hybridization on microtiter plates. Clin Chem. 2000;46:124–6.PubMed Tong D, et al. Detection of p53 polymorphism at codon 72 by PCR and allele-specific oligonucleotide hybridization on microtiter plates. Clin Chem. 2000;46:124–6.PubMed
33.
go back to reference Klug SJ, et al. TP53 Polymorphism, HPV Infection, and Risk of Cervical Cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1009–12.PubMed Klug SJ, et al. TP53 Polymorphism, HPV Infection, and Risk of Cervical Cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1009–12.PubMed
34.
go back to reference Fernandes TA, Lima GL, De Souza FC, Fernandez JV, Meissner RV. Evaluation of the polymorphisms in the exons 2 to 4 of the TP53 in cervical carcinoma patients from a Brazilian population. Mol Biol 2008; 54 Suppl: OL1025–31. Fernandes TA, Lima GL, De Souza FC, Fernandez JV, Meissner RV. Evaluation of the polymorphisms in the exons 2 to 4 of the TP53 in cervical carcinoma patients from a Brazilian population. Mol Biol 2008; 54 Suppl: OL1025–31.
Metadata
Title
Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer
Authors
Patricia Piña-Sánchez
Dulce María Hernández-Hernández
Lucia Taja-Chayeb
Ricardo M. Cerda-Flores
Ana Lilia González-Herrera
Carlos Rodea-Avila
Teresa Apresa-García
Patricia Ostrosky-Wegman
Guelaguetza Vázquez-Ortíz
Patricia Mendoza-Lorenzo
Alfonso Dueñas-González
Mauricio Salcedo
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9599-8

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue